Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Cancer Res. 2019 May 2;79(11):2892–2908. doi: 10.1158/0008-5472.CAN-18-3026

Figure 5. ARF6 is necessary for PI3K and AKT activation.

Figure 5.

(a-c) Adenoviral delivery of MYC-tagged ARF6T27N, a GDP-bound, inactive form of ARF6. (a) Catalytic activity of endogenous PI3K in A2058 human melanoma cells. Unpaired t-test, two tailed. (b) 15 melanoma and one carcinoma (HEY-T30) cell lines were screened for AKT activation. 11/16 (68%) cell lines show reduced pAKTS473 with ARF6T27N expression. (c) Reproducible reduction in pAKT by ARF6T27N expression in A375 cells (n=4), A2058 cells (n=4), and HEY-T30 cells (n=5). (d) Reduced pAKT with siRNA knockdown of ARF6 in SK-MEL-147 (n=5), A2058 (n=4), and CACL (n=4) and HEY-T30 (n=6). See Figure S6 for quantitative data.